No Data
No Data
MedMira Reports Third Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024.Corporate updateIn Q3 FY2024, MedMira focused
MedMira Announces the Hire of Vice President of Business Development
HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of
Medmira Inc. Expands U.S. Presence Amidst Losses
MedMira Reports Second Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024.Corporate updateDuring Q2 FY2024, MedMira r
MedMira Receives Canadian Patent for Its Unique Quantitative Diagnostic System
HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test s
Corporate Update on Clinical Evaluation of MedMira's Products
HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required sub